Clinical Trial Update: Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis [Phase 1]

View source ↗

Summary

This entry reports the completion of a Phase 1 clinical trial evaluating a chimeric fibril-reactive monoclonal antibody designated 11-1F4 in patients with AL am…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: AL Amyloidosis | Phase 1 | Status: COMPLETED